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Kidney Renal Clear Cell Carcinoma (KIRC) is a significant cause of cancer-related deaths. Here, 
we aim to identify the LncRNAs associated with the immune system and characterise their 
clinical utility in KIRC. A total of 504 patients’ data was used from TCGA-GDC. In–silico 
correlation analysis identified 143 LncRNAs associated with immune-related genes (r > 0.7, p-
value < 0.05). K-means consensus method clustered KIRC samples in three immune clusters, 
namely cluster C1, C2, and C3 based on the expression of 143 immune-related LncRNAs. 
Kaplan-Meier analysis showed that C3 patients survived significantly worse than the other two 
clusters (p-value < 0.0001). A comparison of TCGA miRNA, mRNA cluster with immune 
cluster showed the independence and robustness of immune clusters (HR = 2.02 and p-value = 
2.12 X 10-8). The GSEA and CIBERSORT analysis showed high enrichment of poorly activated 
T-cells in C3 patients. To define LncRNA immune prognostic signature, we randomly divided 
the TCGA sample into discovery and validation sets. By utilising multivariate Cox regression 
analysis, we identified and validated a seven LncRNA immune prognostic signature score (LIPS 
score) (HR = 1.43 and p-value = 2.73 X 10-6) in KIRC. Comparison of LIPS score with all the 
clinical factors validated its independence and superiority in KIRC prognosis. In summary, we 
identified LncRNAs associated with the immune system and showed the presence of prognostic 
subtypes of KIRC patients based on immune-related LncRNA expression. We also identified a 
novel immune LncRNA based gene-signature for KIRC patients’ prognostication. 
Introduction: 
Renal cell carcinoma (RCC) accounts for more than 2% of cancer-related deaths in the world 
[1,2]. Histologically, RCC tumors can be placed under several major and rare subtypes. KIRC 
subtype is the most common and aggressive subtype of kidney tumors [3, 4, 5]. Recent genomic 
studies of clear cell carcinoma have dramatically increased our understanding of these tumors 
[5–7]. These studies have also revealed high molecular heterogeneity in these tumors, which 
necessitates further sub-classification of these tumors to improve diagnosis and treatment 
strategies. 
 In the past few years, LncRNAs have attracted a lot of attention due to their striking 
tumor and tissue specificity [8, 9]. In the context of cancer, members of LncRNA group have 









have been implicated in the modulation of the immune system [11]. The immune system plays a 
vital role in tumor development and progression [12]. Thus, it is crucial to identify LncRNAs 
which are involved in the modulation of the immune system. The LncRNAs may prove to be 
useful not only in immunotherapy decisions but may also provide novel therapeutic options.  
 Here we have used guilt by association in-silico analysis to identify the immune-related 
LncRNAs. We also identified a novel prognostic subtype of KIRC patients. Further, we have 
defined the genetic and epigenetic status of these novel prognostic subtypes. Moreover, using 
various statistical methods, we developed and validated a LncRNA immune prognostic signature 
score (LIPS score) for the prognostication of KIRC patients.  
Materials and Methods 
Expression Analysis 
RNA-sequencing data for tumors and normal kidney from KIRC patients was downloaded from 
TCGA-GDC website and analysed using Tuxedo pipeline [13]. In short, reads were mapped 
using TopHat, merged and assembled using cufflinks and cuffmerge [13, 14]. Read count and 
FPKM values were calculated.  
Differential Expression, Correlation Analysis and K-Means Clustering 
Differential expression (DE) analysis was carried out on raw counts using Limma package in R. 
Genes with average count more than zero in tumors and normal kidney were used for differential 
expression analysis. FDR correction was performed to identify the differentially expressed genes 
in KIRC compared to normal kidney. Genes with more than 5-fold expression and 0.05 corrected 
p-value were considered as differentially expressed.  
To identify LncRNAs associated with immune modulating genes correlation analysis was 
performed in the statistical software R. List of genes involved in immune modulation was 
downloaded from innateDB database. LncRNAs with the correlation coefficient ≥ 0.7 and p-
value ≤ 0.05 were used for further analysis. K-Means consensus clustering was done using 143 
immune-related LncRNAs using R. 
 









Gene set enrichment analysis was performed using GSEA software. A pre-ranked method with 
default parameters was used for the analysis. We used hallmark, immunogenic genes sets as 
input. CIBERSORT analysis was done on https://cibersort.stanford.edu/ using the beta version of 
absolute quantification. Average expression of the different clusters was used as mixture file and 
LM22 was used as a signature gene file. GO analysis was performed using 
http://www.geneontology.org/ website. GO biological function was used for analysis. For 
network analysis, https://genemania.org/ was used with default settings [15]. Genes differentially 
expressed in high vs low LIPS score group was used as input.  
Cox Regression and Kaplan-Meier Analysis 
Clinical data associated with KIRC was downloaded from TCGA-GDC website in January 2018. 
TCGA miRNA and mRNA cluster data and Chen et al. cluster data were obtained from the 
supplementary file supplied with TCGA–KIRC study and Chen et al. study respectively [5, 7]. 
Survival package of R was used for univariate and multivariate Cox regression analysis which 
provided hazard ratio, confidence interval (CI) and p-values. The assumptions of Cox model 
were validated using Survival package and the prognostic ability was cross-validated using rms 
package in R. Kaplan-Meier analysis was performed in GraphPad 7.0. 
Development of LIPS score 
Immune LncRNAs identified in correlation analysis were subjected to univariate Cox regression 
analysis in the R survival package. We used immune LncRNA expression data and clinical data 
from the discovery set and performed univariate Cox regression analysis. To define the best 
prognostic immune LncRNA, we used a hazard ratio cut-off of 1.5 and FDR < 0.05. A total of 62 
immune LncRNAs showed significant correlation with survival (FDR < 0.05). To select the 
LncRNAs with highest prognostic ability, a hazard ratio cut-off of 1.5 was applied (either more 
than 1.5 or less than 0.67). Post application of these filtering criteria led to the prediction of 
seven LncRNAs. To develop LncRNA immune prognostic signature (LIPS) score, we combined 
the weighted expression of all the seven LncRNAs for each individual patient. The weights were 
obtained from Cox regression analysis. If the regression coefficient for LncRNAs are defined as 









LIPS score for Patient A = (β1* expression of LncRNA1) + (β2* expression of LncRNA2) + (β3* 
expression of LncRNA3) + (β4* expression of LncRNA4) + (β5* expression of LncRNA5) + 
(β6* expression of LncRNA6) + (β7* expression of LncRNA7) 
Results 
Expression Analysis of Immune Genes in Normal Kidney and KIRC Samples 
To delineate the expression pattern of immune genes, we analysed the TCGA RNA-Seq 
data of KIRC tumors and normal kidney samples. Interestingly, we found that 2378 genes (846 
protein-coding genes and 1532 LncRNA genes) were expressed only in KIRC whereas 669 
genes (235 protein-coding genes and 434 LncRNA genes) were exclusive to normal kidney 
(Figure 1 A and Supplementary Table S1). Nearly twice the number of LncRNAs showed 
KIRC specificity compared to protein-coding genes confirming the previous finding that the 
LncRNAs are more cancer-specific as compared to the protein-coding genes [8]. Limma with 
FDR correction (five-fold expression with the significance cut-off of 0.05) identified 2139 genes 
(1577 protein-coding genes and 562 LncRNA genes) as differentially expressed in KIRC 
(Figure 1 B). As expected, genes previously identified as a marker of KIRC, CA9, ANGPTL4, 
and NDUFA4L2 were found to be overexpressed in KIRC compared to normal (Supplementary 
Figure S1 A). 
Next, we downloaded the list of genes involved in modulation of the immune system from 
www.innatedb.com database. The differential expression analysis was carried out using Limma, 
which identified 130 immune-related genes differentially expressed in KIRC (112 overexpressed 
and 18 underexpressed) (Figure 1 C). As expected, in pathway analysis, all the enriched 
pathways indicated the immune modulation function of input genes (Figure 1 D).  
In-silico Identification of LncRNAs Associated with Immune Pathways 
 Guilt by association is a standard method to identify the probable functions of unknown 
genes [16]. This principle states that genes that are associated are more likely to share a function. 
We utilised guilt by association method to identify the LncRNAs with a high probability of 
immune modulation role in KIRC samples. This analysis identified 143 LncRNAs associated 
with immune genes with more than 0.7 correlation coefficient and less than 0.05 p-value 









SNHG8 and TP73-AS1 (correlation coefficient 0.72 and 0.84 respectively) were also identified in 
our analysis strengthening the analysis pipeline [17, 18].  
Immune-Related LncRNAs are Associated with Prognostic Subtypes of KIRC  
We performed K-means consensus clustering to identify immune LncRNAs associated 
subtypes in KIRC patients. The K-means consensus clustering placed samples into three groups 
that we named, clusters C1, C2 and C3 (Figure 2 A and Supplementary Table S3). The 
expression of immune-related LncRNAs in these novel clusters is shown in Figure 2 B. The 
variable expression of immune LncRNAs in patients belonging to different clusters prompted us 
to investigate the survival pattern of these patients. Strikingly, we discovered an association 
between the expression level of immune LncRNAs and survival where patients from C1 showed 
good prognosis and patients from C3 and C2 showed worst and intermediate prognosis 
respectively (Supplementary Figure S1 B and Figure 2 C). The Cancer Genome Atlas 
(TCGA) in its landmark paper on KIRC has identified miRNA and mRNA subtypes with 
prognostic association [5]. Hence, next, we performed a multivariate Cox regression analysis 
using TCGA miRNA, mRNA and newly identified immune clusters as a covariate. Interestingly, 
our immune cluster outperformed TCGA miRNA, mRNA clusters and predicted survival 
independently (Figure 2 D). Similarly, Chen et al. have identified five genomic clusters in KIRC 
with a significant difference in survival. Excitingly, in multivariate Cox regression analysis, 
immune cluster emerged as most significant and independent prognosticator (Figure 2 D). From 
the TCGA clinical data, we found that C3 patients have significant enrichment of a high-grade 
tumor (Grade-4), higher metastasis rate (M1), and lower average mutation (Supplementary 
Table S3). As C3 patients showed inferior prognosis and different clinical and mutational 
features, we grouped C1, C2 patients and compared with C3 patients. In a Kaplan-Meier plot, C3 
showed four times less median survival compared to combined C1 and C2 patients (Figure 2 C).  
We hypothesised that genetic and epigenetic difference between C3 patients and C1+C2 
patients might explain the reason for differences in survival. To validate our hypothesis, we 
performed Gene Set Enrichment Analysis (GSEA) using differently regulated genes between 
these two groups (Figure 3 A). A pre-ranked GSEA analysis showed enrichment of genes 
associated with CD8 T up, effector CD8 cell down, T regulatory cell down, and Dendritic cell 









S4). KRAS signalling downregulation and upregulation of allograft rejection related genes in 
Cluster 3 (Supplementary Figure S2 E and F and Supplementary Table S4). We also found 
that patients belonging to C3 had high expression of PDCD1 (PD1) and CTLA4 expression 
compared to C1+C2 patients (Supplementary Figure S3). Also, we did not find a significant 
difference of CD274 (PDL1) expression between C1+C2 and C3 patients (Supplementary 
Figure S3). These results suggest the distinct immune cell infiltration in C3 and C1+C2 patients. 
We performed CIBERSORT analysis to identify the infiltration level of various immune cells. 
Interestingly, we found that cluster C3 patients had higher infiltration of CD8+ T-cells (p-value = 
0.03) and C1+C2 patients had higher infiltration of Naïve B-cells, M0 and M2 type macrophages 
and neutrophils (p-values = 0.03, 0.02, < 0.0001, and 0.08) (Figure 3 B). We also showed that 
C3 patients showed the significantly lower number of somatic mutations compared to C1+C2 (p-
value < 0.005) (Figure 3 C and Supplementary Table S4). Further, we explored common 
somatic mutations in C1+C2 and C3 patients using Chen et al. data. As expected, VHL, PBRM1, 
SETD2 and BAP1 were most mutated genes in both the clusters of patients (Figure 3 D and 
Supplementary Table S5). Interestingly, we found that C3 patients had much lower MTOR, 
MLL3, PTEN, ARID1A, STAG2 and NF2 mutations (Figure 3 D). Interestingly, inactivating 
mutation in the one of the frequently mutated genes in cancer, TP53, was absent in C3, (Figure 3 
D, Supplementary Table S5). This data supports our previous finding that C3 patients, in 
general, have a lower mutation rate.  
Comparison of DNA methylation changes showed that C3 patients group, in general, 
have more hyper-methylated genes compared to C1+C2 patients (Supplementary Figure S4). 
This finding supports the previous observation of Chen et al. that KIRC patients with higher 
methylation level show poor survival.  
Immune Associated LncRNA Signature is Robust Prognosticator of KIRC Patients:  
In our earlier analysis, we found that immune-related LncRNAs are associated with prognosis of 
KIRC patients. Therefore, we developed a LncRNA based prognostic signature for KIRC 
patients. As TCGA RNA-Seq data is the only available LncRNA expression data with clinical 
data, we randomly divided the TCGA KIRC RNA-Seq into discovery and validation set (208 
patients each). After applying the filtering criteria, we identified seven immune prognostic 









good prognosis markers (protective LncRNA) (Figure 4 A). Further, we developed a LncRNA 
immune prognostic signature score (LIPS score) for each patient in the discovery set using the 
formula detailed in the method section. We validated the prognostic utility of LIPS score in a 
univariate Cox regression analysis (HR= 1.38, p-value = 5.14 X 10-8) (Table 1). The 
proportionality assumptions of Cox model were tested and it was observed that none of the co-
variates break the assumption and are time independent (Supplementary Table S6). Further, 10-
fold cross-validation (c-index = 0.723) validated the prognostic ability of the proposed model. 
We also performed multivariate analysis of LIPS score with age, distance metastasis and tumor 
stage. As expected LIPS score was an independent predictor of survival in the discovery set (HR 
= 1.38, p-value = 6.00 X 10-4) (Table 1). We next tested the prognostic power of LIPS score in 
the validation set. We performed univariate Cox regression analysis and showed that LIPS score 
was an independent predictor of survival of KIRC patients in the validation set as well (HR = 
1.52, p-value = 2.47 X 10-9) (Table 1). Furthermore, we also executed multivariate analysis of 
LIPS score with age, distance metastasis and tumor stage in the validation and showed again that 
LIPS score was a robust and independent prognosticator in the validation set (HR = 1.43, p-value 
= 2.73 X 10-6).  
 The LIPS score distribution in the discovery and validation sets are presented in Figure 4 
B and 4 C). Interestingly, we found that patients with lower LIPS score showed less mortality in 
both the set of patients (Figures 4 D and E). Next, we divided the patients into low and high 
LIPS score (negative and positive LIPS score) and performed Kaplan-Meier analysis to show 
that patients with low LIPS score survive significantly better than the patients with high LIPS 
score in the discovery set (HR = 3.02 and p-value < 0.0001) and validation set (HR = 3.04 and p-
value < 0.0001) (Figure 4 F and G).  
 We also compared the LIPS score with other previously published signature including 
five LncRNA signature [19, 20]. In a multivariate Cox regression analysis, LIPS score was both 
an independent and superior prognostic marker of KIRC patients (Table 2). The comparison of 
stage, metastasis and mutation between low and high LIPS score patients are shown in 
Supplementary Table S7.  









We noted above that LIPS score signature was consist of two different categories of LncRNAs 
that we termed Risky LncRNAs, for those LncRNA which were associated with poor survival, 
and protective LncRNA which were associated with good survival. As expected, high-risk 
LncRNAs were overexpressed in high LIPS score patients while low-risk LncRNAs were 
overexpressed in patients with lower LIPS score in both the discovery and validation set (Figure 
4 H and I). We hypothesised that LncRNAs which form a part of the LIPS score modulate the 
global pattern of gene expression. As a result, altering various signalling pathways differently 
between low and high LIPS score patients, hence explaining the difference in survival. GO term 
analysis using overexpressed genes in high LIPS score versus low LIPS score (Figure 5 A), 
identified enrichment of pathways involved in acute-phase response, acute-inflammatory 
response, nucleobase-containing compound metabolic process, and cellular nitrogen compound 
metabolic and synthesis process (Figure 5 B). Similarly, GO analysis using genes overexpressed 
in low LIPS score compared to high LIPS score (Figure 5 C) showed enrichment of pathways 




The immune system plays an important role in the development and progression of 
cancers including KIRC [21]. This phenomenon is being exploited to develop various 
immunotherapeutic strategies. However, reasons, why certain tumors are heavily immune 
infiltrated while others show minimal to no immune participation, are still not fully understood. 
Also, among the infiltrated tumors how the immune system is tamed or utilized by the tumors is 
only now being explored. Understanding immune composition and regulatory mechanisms are of 
primary importance to further innovate immunotherapeutic strategies. Recently, Şenbabaoğlu et 
al have shown the importance of immune infiltration on the KIRC patients’ survival. Authors 
have also identified mRNA signature for the patients’ prognosis [22]. Similarly, Giraldo et al 
have identified the role of Tumor-Infiltrating and Peripheral Blood T-cell in the prediction of 
early recurrence in localized RCC [23]. The high tissue and cancer specificity of LncRNAs 
which is useful as biomarker and therapeutic targets, also serves as a great tool to delineate the 









modulate the immune system [24]. Here, we performed an in-silico analysis to identify the 
LncRNAs associated with an immune function in KIRC. We identified three prognostic clusters 
with different survival potential (C1, C2 and C3) using K-means clustering based on these 
immune-related LncRNAs. Interestingly, C1 with the best survival showed expression of 143 
LncRNAs similar to normal while C3 with worst survival have higher expression of LncRNAs 
(Figure 2 B). Immune clusters showed significantly better and independent survival association 
compared to TCGA mRNA and miRNA clusters [5]. 
GSEA analysis revealed that C3 patients had overexpression of genes regulating T-cell 
population but the downregulation of genes involved in the activation of dendritic cells. Using 
CIBERSORT analysis, we also found that C3 patients have higher infiltration of CD8+ T-cells. 
These results suggest that although C3 patients, i.e. patients with worst survival, have higher 
enrichment of CD8+ T-cells, these cells were poorly activated probably due to lack of antigen 
presenting cells (dendritic cells). Interestingly, these patients also showed significantly lower 
mutational burden, hence lower number of neoantigens which corroborate with reduced 
activation of CD8+ T-cells [25]. These findings were further confirmed by the fact that patients 
belonging to C3 had high expression of PDCD1 (PD1) and CTLA4 expression compared to 
C1+C2 patients. Also, we did not find a significant difference of CD274 (PDL1) expression 
between C1+C2 and C3 patients (Supplementary Figure S3). This difference in the level of 
PD1 and CTLA4 between C1+C2 and C3 indicating high infiltration but poor activation of T-
cells. On the other hand, patients from C1+C2 had higher infiltration of Naïve B-cells, M0 and 
M2 type macrophages and neutrophils. The infiltration of neutrophils is associated with 
favourable prognosis of many cancer types [26, 27]. The high neutrophil level in C1+C2 
suggests its involvement in a better prognosis.  
To utilise the immune-associated LncRNAs in prognosis, we developed a seven LncRNA 
based immune score LIPS score. We showed that LIPS score was an independent marker of 
prognosis in the discovery and validation sets and high LIPS score was associated with poor 
survival. We also compared the prognostic ability of LIPS score with previously developed 
prognostic signature. In a multivariate analysis, LIPS score outperformed both the previous 
prognostic signatures. We hypothesise that gene expression differences between high and low 









analysis showed that patients with high LIPS score had activation of immune-related pathways, 
suggesting the involvement of the immune system in the prognosis of these patients. In 
comparison, low LIPS score patients showed enrichment of pathways involved in transport and 
localization suggesting the differential role of these pathways in low LIPS score patients 
compared to high LIPS score patients.  
In conclusion, RNA-Seq analysis identified novel prognostic immune subtype in KIRC 
patients characterised by differential expression of immune-related LncRNAs. The variation in 
the immune subtypes and the level of immune cell infiltration may explain the prognostic 
differences. More importantly, we have developed and validated a strong and robust immune 
LncRNA prognostic signature which was used to formulate LIPS score for KIRC patients.  
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Figure 1. Expression of Immune Genes in KIRC: A) Venn diagram shows overlaps among the 
different categories of gene sets. B) Volcano plot represents the result of differentially expressed 
genes (DEGs) analysis of KIRC vs normal kidney (under-expressed: 
 and FDR < 0.05; over-expressed:  and 
FDR < 0.05). C) The heat map shows the expression level of differentially expressed immune-
related genes in KIRC samples compared to normal tissues (blue- lower expression, red- higher 
expression). D) Bar plot represents the enriched GO terms obtained using differentially 
expressed immune genes in KIRC.  
Figure 2. K-means Clustering Identifies Novel KIRC Prognostic Subtype: A) Results 
obtained from K-means consensus clustering identified three different clusters namely C1(light 
blue), C2(dark blue) and C3(green) B) Heatmap of immune-related LncRNA expression in the 
three KIRC clusters and normal samples. C) Kaplan-Meier plot shows the difference in survival 
of patients belonging to C1+C2 and C3 clusters. D) The table summarises the results of the 
multivariate analysis performed to compare the prognostic value of TCGA miRNA, mRNA 
clusters with immune clusters identified in this study. The table also shows the results of the 
multivariate analysis conducted to compare the prognostic value of genomic clusters of KIRC as 









Figure 3. Characterization of immune C3 compared to C1+C2: A) Volcano plot represents 
the protein coding genes differentially expressed in C1+C2 compared to C3. B) Bar plot shows 
the level of different immune cell types in C1+C2 and C3. C) Box plot represents the degree of 
mutation in C1+C2 and C3 patients. D) Waterfall plot represents the frequency of the common 
mutations in C1+C2 and C3. The key is given to interpret the results.  
Figure 4. Development of LIPS score: A) Volcano plot represents the prognostic immune 
LncRNAs that significantly predict KIRC patient’s prognosis. Red spots indicate LncRNAs 
associated with poor survival (risky) and blue spots indicate LncRNAs that are associated with 
good survival marker (protective). A dot plot shows the distribution of LIPS score in B) 
discovery set and C) validation set. A dot plot shows the distribution of LIPS score with survival 
in D) discovery set and E) validation set (blue- patients alive, red- patients dead). A Kaplan-
Meier plot shows the difference in survival of KIRC patients belonging to high and low LIPS 
score in F) discovery set and G) validation set. The patients were divided at 0 LIPS score. 
Heatmap showing the expression of seven immune prognostic LncRNA in H) discovery set and 
I) validation set.  
Figure 5. Molecular Characterization of High and Low LIPS Patients: A) Heat map 
represents the expression of differentially expressed genes in high vs low LIPS patients (white- 
lower expression, red- higher expression (upregulated: 434, downregulated: 52)). B) An XY plot 
shows the GO terms enriched in patients with high LIPS score (blue- negative enriched GO 
terms, red- positive enriched GO terms, size represents the fold change). C) An XY plot shows 
the GO terms enriched in patients with low LIPS score (blue- negative enriched GO terms, red- 
positive enriched GO terms, size represents the fold change).  
 
 
Table 1: Table showing the results of univariate and multivariate cox regression analysis performed 
to compare prognostic value of clinical variate with LIPS score developed in this study. 
 













Distance Metastasis  M1 1.53 2.93 6.56 5.34 X 10-11 
Stage 
Stage II 1.54 0.64 3.744 0.33 
Stage III 3.1 1.7 5.65 2.00 X 10-4 
Stage IV 7.25 3.96 13.27 1.28 X 10-10 
Grade Not significant 
Regional lymph nodes (N) Not significant 
Age 1.03 1.009 1.05 4.20 X 10-3 
Score 1.38 1.23 1.55 5.14 X 10-8 
Multivariate analysis 
Distance Metastasis M1 5.64 0.85 37.23 0.07 
Stage 
Stage II 1.21 1.13 2.97 0.67 
Stage III 3.1 0.14 4.08 0.01 
Stage IV 7.25 0.14 7.35 0.96 
Age 1.01 0.99 1.03 0.13 
Score 1.38 1.23 1.55 6.00 X 10-4 
Validation cohort Cox regression analysis 
Univariate analysis 
Variable   HR 95% CI P value 
Distance Metastasis M1 3.39 2.03 5.67 3.18 X 10-6 
Stage 
Stage II 1.54 0.29 2.49 0.77 
Stage III 3.1 0.84 3.2 0.14 
Stage IV 7.25 2.39 7.86 1.34 X 10-6 
Grade Not significant 
Regional lymph nodes (N) Not significant 
Age 1.05 1.03 1.07 9.76 X 10-6 
Score 
 
1.52 1.32 1.75 2.47 X 10-9 
Multivariate analysis 
Distance Metastasis M1 0.18 0.02 1.26 0.41 
 Stage 
Stage II 0.78 0.26 2.95 0.65 
Stage III 1.44 0.73 2.84 0.28 
Stage IV 17.27 2.43 122.6 0.02 
Age 1.06 1.03 1.08 3.03 X 10-6 
Score 1.43 1.24 1.65 2.73 X 10-6 
  
 
Table 2: Table showing the results of multivariate analysis performed to compare prognostic value 
of previously published gene signatures with LIPS score developed in this study.  
Comparison of signatures 
Discovery set 









  Lower  Upper  
LncRNA signature (Shi et. al. ) 1.006 0.99 1.01 0.26 
5 PcG signature ( Chen et.al.) 1.03 1.01 1.04 0.01 
LIPS 1.42 1.22 1.66 7.09 X 10-6 
Validation set 
LncRNA signature (Shi et. al. ) 1.01 0.99 1.03 0.06 
5 PcG signature ( Chen et.al.) 1.01 0.99 1.03 0.12 


























































figure 5 . 
 
